<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DDAVP- desmopressin acetate injection </strong><br>Ferring Pharmaceuticals Inc.<br></p></div>
<h1>DDAVP<span class="Sup">®</span> Injection<br>(desmopressin acetate)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">4 mcg/mL</span></p>
<p><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><span class="Bold">DDAVP<span class="Sup">®</span> ACETATE Injection</span> (desmopressin acetate) 4 mcg/mL is a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation. It is chemically defined as follows:</p>
<p>Mol. Wt. 1183.34</p>
<p>Empirical Formula: C<span class="Sub">46</span>H<span class="Sub">64</span>N<span class="Sub">14</span>O<span class="Sub">12</span>S<span class="Sub">2</span>∙C<span class="Sub">2</span>H<span class="Sub">4</span>O<span class="Sub">2</span>∙3H<span class="Sub">2</span>O</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=651f6fee-a2c7-431b-8d5d-58b156c72244&amp;name=ddavp-01.jpg"></div>
<p>1-(3-mercaptopropionic acid)-8-D-arginine vasopressin monoacetate (salt) trihydrate.</p>
<p><span class="Bold">DDAVP Injection</span> 4 mcg/mL is provided as a sterile, aqueous solution for injection.</p>
<table class="Noautorules" width="75%">
<col align="left" valign="top" width="33%">
<col align="left" valign="top" width="34%">
<col align="left" valign="top" width="33%">
<tbody class="Headless">
<tr>
<td align="left">Each mL provides:</td>
<td align="left">Desmopressin acetate</td>
<td align="left">4.0 mcg</td>
</tr>
<tr>
<td align="left"></td>
<td align="left">Sodium chloride</td>
<td align="left">9.0 mg </td>
</tr>
<tr>
<td align="left"></td>
<td align="left" colspan="2">Hydrochloric acid to adjust pH to 4</td>
</tr>
</tbody>
</table>
<p>The 10 mL vial contains chlorobutanol as a preservative (5.0 mg/mL).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><span class="Bold">DDAVP Injection</span> 4 mcg/mL contains as active substance, desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin. One mL (4 mcg) of DDAVP (desmopressin acetate) solution has an antidiuretic activity of about 16 IU; 1 mcg of DDAVP is equivalent to 4 IU.</p>
<p>DDAVP has been shown to be more potent than arginine vasopressin in increasing plasma levels of factor VIII activity in patients with <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> and von Willebrand's disease Type I.</p>
<p>Dose-response studies were performed in healthy persons, using doses of 0.1 to 0.4 mcg/kg body weight, infused over a 10-minute period. Maximal dose response occurred at 0.3 to 0.4 mcg/kg. The response to DDAVP of factor VIII activity and <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activator is dose-related, with maximal plasma levels of 300 to 400 percent of initial concentrations obtained after infusion of 0.4 mcg/kg body weight. The increase is rapid and evident within 30 minutes, reaching a maximum at a point ranging from 90 minutes to two hours. The factor VIII related antigen and ristocetin cofactor activity were also increased to a smaller degree, but still are dose-dependent.</p>
<ol>
<li>The biphasic half-lives of DDAVP were 7.8 and 75.5 minutes for the fast and slow phases, respectively, compared with 2.5 and 14.5 minutes for lysine vasopressin, another form of the hormone. As a result, DDAVP provides a prompt onset of antidiuretic action with a long duration after each administration.</li>
<li>The change in structure of arginine vasopressin to DDAVP has resulted in a decreased vasopressor action and decreased actions on visceral smooth muscle relative to the enhanced antidiuretic activity, so that clinically effective antidiuretic doses are usually below threshold levels for effects on vascular or visceral smooth muscle.</li>
<li>When administered by injection, DDAVP has an antidiuretic effect about ten times that of an equivalent dose administered intranasally.</li>
<li>The bioavailability of the subcutaneous route of administration was determined qualitatively using urine output data. The exact fraction of drug absorbed by that route of administration has not been quantitatively determined.</li>
<li>The percentage increase of factor VIII levels in patients with mild <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> and von Willebrand's disease was not significantly different from that observed in normal healthy individuals when treated with 0.3 mcg/kg of DDAVP infused over 10 minutes.</li>
<li><span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">Plasminogen</span> activator activity increases rapidly after DDAVP infusion, but there has been no clinically significant <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> in patients treated with DDAVP.</li>
<li>The effect of repeated DDAVP administration when doses were given every 12 to 24 hours has generally shown a gradual diminution of the factor VIII activity increase noted with a single dose. The initial response is reproducible in any particular patient if there are 2 or 3 days between administrations.</li>
</ol>
<div class="Section" data-sectionCode="43682-4">
<a name="Human_Pharmacokinetics"></a><a name="section-3.1"></a><p></p>
<h2>Human Pharmacokinetics</h2>
<p class="First">DDAVP is mainly excreted in the urine. A pharmacokinetic study conducted in healthy volunteers and patients with mild, moderate, and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (n=24, 6 subjects in each group) receiving single dose desmopressin acetate (2 mcg) injection demonstrated a difference in DDAVP terminal half-life. Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (See <span class="Bold"><a href="#Contraindications">CONTRAINDICATIONS</a></span>.) </p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">Hemophilia A</span></h2>
<p class="First"><span class="Bold">DDAVP Injection</span> 4 mcg/mL is indicated for patients with <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> with factor VIII coagulant activity levels greater than 5%.</p>
<p>DDAVP will often maintain hemostasis in patients with <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure.</p>
<p>DDAVP will also stop <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> patients with episodes of spontaneous or <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>-induced injuries such as hemarthroses, intramuscular <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> or mucosal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<table class="Noautorules" width="100%">
<col align="left" valign="top" width="100%">
<tbody class="Headless"><tr><td class="Botrule Lrule Rrule Toprule" align="left">DDAVP is not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> B, or in patients who have factor VIII antibodies.</td></tr></tbody>
</table>
<p>In certain clinical situations, it may be justified to try DDAVP in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2>von Willebrand's Disease (Type I)</h2>
<p class="First"><span class="Bold">DDAVP Injection</span> 4 mcg/mL is indicated for patients with mild to moderate classic von Willebrand's disease (Type I) with factor VIII levels greater than 5%. DDAVP will often maintain hemostasis in patients with mild to moderate von Willebrand's disease during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure.</p>
<p>DDAVP will usually stop <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in mild to moderate von Willebrand's patients with episodes of spontaneous or <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>-induced injuries such as hemarthroses, intramuscular <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> or mucosal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p>Those von Willebrand's disease patients who are least likely to respond are those with severe homozygous von Willebrand's disease with factor VIII coagulant activity and factor VIII von Willebrand factor antigen levels less than 1%. Other patients may respond in a variable fashion depending on the type of molecular defect they have. <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">Bleeding time</span> and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked during administration of DDAVP to ensure that adequate levels are being achieved.</p>
<p>DDAVP is not indicated for the treatment of severe classic von Willebrand's disease (Type I) and when there is evidence of an abnormal molecular form of factor VIII antigen. (See <span class="Bold"><a href="#Warnings">WARNINGS</a>.</span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">Diabetes Insipidus</span></h2>
<p class="First"><span class="Bold">DDAVP Injection</span> 4 mcg/mL is indicated as antidiuretic replacement therapy in the management of central (cranial) <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span> and for the management of the temporary <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> and <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span> following head <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> or surgery in the pituitary region. DDAVP is ineffective for the treatment of <span class="product-label-link" type="condition" conceptid="438476" conceptname="Nephrogenic diabetes insipidus">nephrogenic diabetes insipidus</span>.</p>
<p>DDAVP is also available as an intranasal preparation. However, this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate. These include poor intranasal absorption, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span> and blockage, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">nasal discharge</span>, <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of nasal mucosa, and severe atrophic <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>. Intranasal delivery may be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy, create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Contraindications"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="Bold">DDAVP Injection</span> 4 mcg/mL is contraindicated in individuals with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to desmopressin acetate or to any of the components of <span class="Bold">DDAVP Injection</span> 4 mcg/mL.</p>
<p>DDAVP is contraindicated in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (defined as a creatinine clearance below 50 mL/min).</p>
<p>DDAVP is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> or a history of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<ol>
<li>Very rare cases of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> have been reported from world-wide postmarketing experience in patients treated with DDAVP (desmopressin acetate). DDAVP is a potent antidiuretic which, when administered, may lead to <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span> and/or <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>. Unless properly diagnosed and treated <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> can be fatal. Therefore, fluid restriction is recommended and should be discussed with the patient and/or guardian. Careful medical supervision is required.</li>
<li>When DDAVP Injection is administered to patients who do not have need of antidiuretic hormone for its antidiuretic effect, in particular in pediatric and geriatric patients, fluid intake should be adjusted downward to decrease the potential occurrence of <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span> and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>. (See <span class="Bold"><a href="#Pediatric_Use">PRECAUTIONS, Pediatric Use</a></span> and <span class="Bold"><a href="#Geriatric_Use">Geriatric Use</a></span>.) All patients receiving DDAVP therapy should be observed for the following signs or symptoms associated with <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, decreased serum sodium, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, depressed reflexes, loss of appetite, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span> and abnormal mental status such as <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, decreased consciousness and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>. Severe symptoms may include one or a combination of the following: <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and/or <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>. Particular attention should be paid to the possibility of the rare occurrence of an extreme decrease in plasma <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> that may result in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> which could lead to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.</li>
<li>DDAVP should not be used to treat patients with Type IIB von Willebrand's disease since platelet aggregation may be induced.</li>
<li>DDAVP should be used with caution in patients with habitual or <span class="product-label-link" type="condition" conceptid="4049477" conceptname="Psychogenic polydipsia">psychogenic polydipsia</span> who may be more likely to drink excessive amounts of water, putting them at greater risk of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">For injection use only.</p>
<p><span class="Bold">DDAVP Injection</span> (desmopressin acetate) 4 mcg/mL has infrequently produced changes in blood pressure causing either a slight elevation in blood pressure or a transient <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> and a compensatory increase in heart rate. The drug should be used with caution in patients with coronary artery insufficiency and/or hypertensive cardiovascular disease.</p>
<p>DDAVP (desmopressin acetate) should be used with caution in patients with conditions associated with fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, such as <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disorders</span>, because these patients are prone to <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
<p>There have been rare reports of thrombotic events following <span class="Bold">DDAVP Injection</span> 4 mcg/mL in patients predisposed to thrombus formation. No causality has been determined, however, the drug should be used with caution in these patients.</p>
<p>Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> have been reported rarely. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> has been reported rarely with intravenous and intranasal DDAVP, including isolated cases of fatal <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> with intravenous DDAVP. It is not known whether antibodies to <span class="Bold">DDAVP Injection</span> 4 mcg/mL are produced after repeated injections.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">Hemophilia A</span></h2>
<p class="First">Laboratory tests for assessing patient status include levels of factor VIII coagulant, factor VIII antigen and factor VIII ristocetin cofactor (von Willebrand factor) as well as <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">activated partial thromboplastin time</span>. Factor VIII coagulant activity should be determined before giving DDAVP for hemostasis. If factor VIII coagulant activity is present at less than 5% of normal, DDAVP should not be relied on.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>von Willebrand's Disease</h2>
<p class="First">Laboratory tests for assessing patient status include levels of factor VIII coagulant activity, factor VIII ristocetin cofactor activity, and factor VIII von Willebrand factor antigen. The skin <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> may be helpful in following these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">Diabetes Insipidus</span></h2>
<p class="First"> Laboratory tests for monitoring the patient include urine volume and <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span>. In some cases, plasma <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> may be required.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.5"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Although the pressor activity of DDAVP is very low compared with the antidiuretic activity, use of doses as large as 0.3 mcg/kg of DDAVP with other pressor agents should be done only with careful patient monitoring. The concomitant administration of drugs that may increase the risk of <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span> with <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, NSAIDs, lamotrigine and carbamazepine) should be performed with caution.</p>
<p>DDAVP has been used with epsilon aminocaproic acid without adverse effects.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.6"></a><p></p>
<h2>Carcinogenicity, Mutagenicity, Impairment of Fertility</h2>
<p class="First">Studies with DDAVP have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.7"></a><p></p>
<h2>Pregnancy Category B</h2>
<p class="First">Fertility studies have not been done. Teratology studies in rats and rabbits at doses from 0.05 to 10 mcg/kg/day (approximately 0.1 times the maximum systemic human exposure in rats and up to 38 times the maximum systemic human exposure in rabbits based on surface area, mg/m<span class="Sup">2</span>) revealed no harm to the fetus due to DDAVP. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
<p>Several publications of desmopressin acetate's use in the management of <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span> during pregnancy are available; these include a few anecdotal reports of congenital anomalies and low birth weight babies. However, no causal connection between these events and desmopressin acetate has been established. A fifteen year, Swedish epidemiologic study of the use of desmopressin acetate in pregnant women with <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span> found the rate of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> to be no greater than that in the general population; however, the statistical power of this study is low. As opposed to preparations containing natural hormones, desmopressin acetate in antidiuretic doses has no uterotonic action and the physician will have to weigh the therapeutic advantages against the possible risks in each case.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">There have been no controlled studies in nursing mothers. A single study in postpartum women demonstrated a marked change in plasma, but little if any change in assayable DDAVP in breast milk following an intranasal dose of 10 mcg. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when DDAVP is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Pediatric_Use"></a><a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Use in infants and pediatric patients will require careful fluid intake restriction to prevent possible <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> and <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span>. Fluid restriction should be discussed with the patient and/or guardian. (See <span class="Bold"><a href="#Warnings">WARNINGS</a>.</span>) <span class="Bold">DDAVP Injection</span> 4 mcg/mL <span class="Italics">should not be used in infants less than three months of age</span> in the treatment of <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> or von Willebrand's disease; safety and effectiveness in pediatric patients under 12 years of age with <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span> have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Geriatric_Use"></a><a name="section-7.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of DDAVP Injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. DDAVP is contraindicated in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (defined as a creatinine clearance below 50 mL/min). (See <span class="Bold"><a href="#Human_Pharmacokinetics">CLINICAL PHARMACOLOGY, Human Pharmacokinetics</a>, 									</span> and <span class="Bold"><a href="#Contraindications">CONTRAINDICATIONS</a>.</span>) </p>
<p>Use of DDAVP injection in geriatric patients will require careful fluid intake restrictions to prevent possible <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> and <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span>. Fluid restriction should be discussed with the patient. (See <span class="Bold"><a href="#Warnings">WARNINGS</a>.</span>)</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Infrequently, DDAVP has produced transient <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, mild <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span> and vulval <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. These symptoms disappeared with reduction in dosage. Occasionally, injection of DDAVP has produced local <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or burning <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Occasional <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span> has been reported with the administration of DDAVP. <span class="Bold">DDAVP Injection</span> has infrequently produced changes in blood pressure causing either a slight elevation or a transient <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> and a compensatory increase in heart rate. Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been reported rarely with <span class="Bold">DDAVP Injection</span>.</p>
<p>See <span class="Bold"><a href="#Warnings">WARNINGS</a></span> for the possibility of <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span> and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Post Marketing</h2>
<p class="First">There have been rare reports of thrombotic events (acute cerebrovascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>) following <span class="Bold">DDAVP Injection</span> in patients predisposed to thrombus formation, and rare reports of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremic</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> associated with concomitant use with the following medications: oxybutinin and imipramine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Signs of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may include <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, continuing <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, problems with passing urine and rapid <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. (See <span class="Bold"><a href="#Warnings">WARNINGS</a></span>.) In case of overdosage, the dosage should be reduced, frequency of administration decreased, or the drug withdrawn according to the severity of the condition.</p>
<p>There is no known specific antidote for desmopressin acetate or <span class="Bold">DDAVP Injection</span> 4 mcg/mL.</p>
<p>An oral LD<span class="Sub">50</span> has not been established. An intravenous dose of 2 mg/kg in mice demonstrated no effect.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">Hemophilia A</span> and von Willebrand's Disease (Type I)</h2>
<p class="First"><span class="Bold">DDAVP Injection</span> 4 mcg/mL is administered as an intravenous infusion at a dose of 0.3 mcg DDAVP/kg body weight diluted in sterile physiological saline and infused slowly over 15 to 30 minutes. In adults and children weighing more than 10 kg, 50 mL of diluent is recommended; in children weighing 10 kg or less, 10 mL of diluent is recommended. Blood pressure and pulse should be monitored during infusion. If <span class="Bold">DDAVP Injection</span> 4 mcg/mL is used preoperatively, it should be administered 30 minutes prior to the scheduled procedure.</p>
<p>The necessity for repeat administration of DDAVP or use of any blood products for hemostasis should be determined by laboratory response as well as the clinical condition of the patient. The tendency toward <span class="product-label-link" type="condition" conceptid="4052861" conceptname="Tachyphylaxis">tachyphylaxis</span> (lessening of response) with repeated administration given more frequently than every 48 hours should be considered in treating each patient.</p>
<p>Fluid restriction should be observed. (See <span class="Bold"><a href="#Warnings">WARNINGS</a>, 									</span><span class="Bold"><a href="#Pediatric_Use">PRECAUTIONS, Pediatric Use</a></span> and <span class="Bold"><a href="#Geriatric_Use">Geriatric Use</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">Diabetes Insipidus</span></h2>
<p class="First">This formulation is administered subcutaneously or by direct intravenous injection. <span class="Bold">DDAVP Injection</span> 4 mcg/mL dosage must be determined for each patient and adjusted according to the pattern of response. Response should be estimated by two parameters: adequate duration of sleep and adequate, not excessive, water turnover.</p>
<p>The usual dosage range in adults is 0.5 mL (2.0 mcg) to 1 mL (4.0 mcg) daily, administered intravenously or subcutaneously, usually in two divided doses. The morning and evening doses should be separately adjusted for an adequate diurnal rhythm of water turnover. For patients who have been controlled on intranasal DDAVP and who must be switched to the injection form, either because of poor intranasal absorption or because of the need for surgery, the comparable antidiuretic dose of the injection is about one-tenth the intranasal dose.</p>
<p>Fluid restriction should be observed. (See <span class="Bold"><a href="#Warnings">WARNINGS</a></span>, <span class="Bold"><a href="#Pediatric_Use">PRECAUTIONS, Pediatric Use</a></span> and <span class="Bold"><a href="#Geriatric_Use">Geriatric Use</a></span>.)</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See <span class="Bold"><a href="#Human_Pharmacokinetics">CLINICAL PHARMACOLOGY, Human Pharmcokinetics</a></span>, <span class="Bold"><a href="#Contraindications">CONTRAINDICATIONS</a></span>, and <span class="Bold"><a href="#Geriatric_Use">PRECAUTIONS, Geriatric Use</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.4"></a><p></p>
<h2>Directions for use of One Point Cut (OPC) Ampules for DDAVP Injection</h2>
<ol>
<li>Use aseptic technique to clean ampule. Gently tap the top of the ampule to assist the flow of the solution from the upper portion of the ampule to the lower portion.</li>
<li>Locate the blue dot on the upper portion of the ampule. <span class="Bold">Below</span> this dot is a small score on the neck of the ampule. Hold the ampule with the blue dot <span class="Bold">facing away from you</span>.</li>
<li>Cover the vial with an appropriate wipe. Apply pressure to the top and bottom portions of the ampule to snap the ampule open away from you.</li>
</ol>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">DDAVP Injection</span> 4 mcg/mL is available as a sterile solution in cartons of ten 1 mL single-dose ampules (NDC 55566-2300-0) and in 10 mL multiple-dose vials (NDC 55566-2200-0), each containing 4.0 mcg DDAVP per mL.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<p class="First">Store refrigerated 2 to 8°C (36 to 46°F).</p>
<p><span class="Bold">Keep out of the reach of children.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First">Manufactured for:<br>FERRING PHARMACEUTICALS INC.<br>PARSIPPANY, NJ 07054</p>
<p>Origin Sweden</p>
<p>Rev. 12/2014</p>
<p>2009053645</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - Ten 1 mL Ampule Carton</h1>
<p class="First">NDC-55566-2200-0</p>
<p><span class="Bold">DDAVP<span class="Sup">®</span><br>Injection</span><br><span class="Italics">desmopressin<br>acetate</span></p>
<p><span class="Bold">4</span> µg/mL</p>
<p>PRESERVATIVE FREE<br>FOR INJECTION USE ONLY</p>
<p><span class="Bold">Ten </span>1 mL Ampules</p>
<p><span class="Bold">FERRING</span><br>PHARMACEUTICALS</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - Ten 1 mL Ampule Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=651f6fee-a2c7-431b-8d5d-58b156c72244&amp;name=ddavp-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - One 10 mL Vial Carton</h1>
<p class="First">NDC 55566-2300-0</p>
<p><span class="Bold">DDAVP<span class="Sup">®</span><br>Injection</span><br><span class="Italics">desmopressin<br>acetate</span></p>
<p><span class="Bold">4</span> µg/mL</p>
<p>FOR INJECTION USE ONLY</p>
<p><span class="Bold">One </span>10 mL Vial</p>
<p><span class="Bold">FERRING</span><br>PHARMACEUTICALS</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - One 10 mL Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=651f6fee-a2c7-431b-8d5d-58b156c72244&amp;name=ddavp-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DDAVP 		
					</strong><br><span class="contentTableReg">desmopressin acetate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55566-2200</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Desmopressin Acetate</strong> (desmopressin) </td>
<td class="formItem">Desmopressin Acetate</td>
<td class="formItem">4 ug  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Chloride</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Chlorobutanol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Hydrochloric Acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55566-2200-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, MULTI-DOSE; Combination Product Type = C102839</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018938</td>
<td class="formItem">03/30/1984</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DDAVP 		
					</strong><br><span class="contentTableReg">desmopressin acetate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55566-2300</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Desmopressin Acetate</strong> (desmopressin) </td>
<td class="formItem">Desmopressin Acetate</td>
<td class="formItem">4 ug  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Chloride</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Chlorobutanol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Hydrochloric Acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55566-2300-0</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 AMPULE; Combination Product Type = C102839</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018938</td>
<td class="formItem">03/30/1984</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Ferring Pharmaceuticals Inc.
							(103722955)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Ferring GmbH</td>
<td class="formItem"></td>
<td class="formItem">328609615</td>
<td class="formItem">MANUFACTURE(55566-2200, 55566-2300), ANALYSIS(55566-2200, 55566-2300), PACK(55566-2200, 55566-2300), LABEL(55566-2200, 55566-2300)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Rechon Life Science AB</td>
<td class="formItem"></td>
<td class="formItem">775207769</td>
<td class="formItem">MANUFACTURE(55566-2200, 55566-2300), ANALYSIS(55566-2200, 55566-2300), PACK(55566-2200, 55566-2300), LABEL(55566-2200, 55566-2300)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ebab4450-8a4b-49fc-8a2f-1e480a8b4f77</div>
<div>Set id: 651f6fee-a2c7-431b-8d5d-58b156c72244</div>
<div>Version: 1</div>
<div>Effective Time: 20141222</div>
</div>
</div> <div class="DistributorName">Ferring Pharmaceuticals Inc.</div></p>
</body></html>
